Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Levothyroxine sodium
Intervet Ireland Limited
QH03AA01
Levothyroxine sodium
1 milligram(s)/millilitre
Oral solution
POM: Prescription Only Medicine as defined in relevant national legislation
Dogs
levothyroxine sodium
Hormone
Authorised
2007-06-29
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Leventa 1 mg/ml oral solution for dogs. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains Active substance: Levothyroxine sodium (as multihydrate) 1 milligram (equivalent to 0.97 milligram levothyroxine) Excipients: Ethanol 96 % 0.15 ml For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Oral solution. Clear, slight reddish coloured solution. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Treatment of hypothyroidism in dogs. 4.3 CONTRAINDICATIONS Do not use in dogs with hyperthyroidism or uncorrected adrenal insufficiency (hypoadrenocorticism). Do not use in case of hypersensitivity to levothyroxine sodium or to any of the excipients. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _D_ _a_ _t_ _e_ _ _ _P_ _r_ _i_ _n_ _t_ _e_ _d_ _ _ _2_ _2_ _/_ _0_ _4_ _/_ _2_ _0_ _1_ _6_ _C_ _R_ _N_ _ _ _7_ _0_ _2_ _3_ _2_ _7_ _7_ _p_ _a_ _g_ _e_ _ _ _n_ _u_ _m_ _b_ _e_ _r_ _:_ _ _ _1_ 4.5 SPECIAL PRECAUTIONS FOR USE I) SPECIAL PRECAUTIONS FOR USE IN ANIMALS The product should be used with caution in dogs with cardiac disease, diabetes mellitus or treated adrenal insufficiency (hypoadrenocorticism). For these dogs, gradual introduction of levothyroxine therapy, starting with 25% of the normal dose and increasing by 25% increments every two weeks until optimal stabilisation is achieved is recommended. The clinical diagnosis of hypothyroidis Read the complete document